AbbVie preformulation is an early discovery biologics group working to optimise antibodies prior to downstream assays and clinical delivery.
Join Brittney Mills, PhD, as she explains how AbbVie uses the Prometheus to evaluate conformational and colloidal stability of their candidates. She will discuss the goals of their early formulations group; how Prometheus nanoDSF compares to DSC and its advantages in material usage; the predictive merits of data derived from Prometheus; and how accelerated stability studies validate the initial screening parameters.